Overall rank by patents
#26,261
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 4 technology areas, active 2015–2020. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
The verdict
Epicentre holds 10 US patents across 4 technology areas, rank #26,261 of 50,000 tracked assignees.
Epicentre Technologies Corporation has been granted 10 US utility patents between 2015 and 2020, placing Epicentre Technologies Corporation at rank #26,261 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.5 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Epicentre Technologies Corporation is one of the more focused assignees in the PatentsView dataset. By volume, Epicentre sits between Enteromedics Inc. (10 patents, rank #26,257) and Essence Smartcare Ltd. (10 patents, rank #26,265) - the closest US assignees by grant volume. The composite Innovation Score of 27.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 9 in the 2015–2019 window, a -89% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Epicentre Technologies Corporation's 20.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Epicentre Technologies Corporation against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
EnteroMedics Inc.
10 patents
Enterprise Electronics LLC
10 patents
Enverus, Inc.
10 patents
Environmental Management Confederation, Inc.
10 patents
Ergon, Inc.
10 patents
Ernst & Young U.S. LLP
10 patents
Escape Therapeutics, Inc.
10 patents
Essence Smartcare Ltd.
10 patents
Epicentre Technologies Corporation
10 patents
What this shows Epicentre holds 10 patents at rank #26,261, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Epicentre's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
28 Top 76% higher than 24% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 4 | 40.0% |
| 2017 | 2 | 20.0% |
| 2018 | 1 | 10.0% |
| 2019 | 2 | 20.0% |
| 2020 | 1 | 10.0% |
Top 4 of 4 technology areas
Overall rank by patents
#26,261
Across all tracked assignees
27.6 out of 100
How to use this portfolio
Epicentre's 10 grants land it in the top 76% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.